Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Jun 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for peanut allergy using a medication called tezepelumab along with peanut oral immunotherapy (OIT). The goal is to see if this combination can help people with peanut allergies become less sensitive to peanuts and safely eat them again. The study will involve 62 participants aged 12 to 55 who have had allergic reactions to peanuts and can tolerate a small amount during testing. Participants must be able to give informed consent, and if they are minors, their parent or guardian must also consent.

If you join this trial, you'll go through three phases: first, you'll receive either tezepelumab or a placebo (a dummy treatment) for 8 weeks; then, for 56 weeks, you'll gradually increase your intake of peanut products while continuing the treatment; finally, there will be a 12-week period after stopping the treatment to see how your body responds without it. Throughout the study, participants will be closely monitored for safety and effectiveness. It’s important to note that certain medical conditions or recent treatments may prevent someone from participating, so potential participants should discuss their medical history with the study team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participant and/or parent/legal guardian must be able to understand and provide informed consent (parental permission and informed assent of minor, if applicable)
• • 2. A personal history of an allergic reaction to peanut ingestion
• • 3. A positive reaction at or below ingestion of 100 mg of peanut protein in a single dose (\<= 144 milligram cumulative dose) during the screening Double-Blind Placebo-Controlled Food Challenge (DBPCFC)
• • 4. A negative challenge to the placebo (oat) during the Screening DBPCFC
• 5. Sensitization to peanut as evidenced by either one of the following:
• • 1. positive sIgE to Ara h2 \>= 0.35 kilounit per liter by ImmunoCAP (TM) testing, or
• • 2. wheal \>= 3 mm on skin prick test to peanut extract compared to a negative control
• • 6. Female participants of childbearing potential must have a negative pregnancy test upon study entry
• • 7. Female participants with reproductive potential must agree to use an FDA approved method of contraception for the duration of the study
• • 8. Willing and able to comply with the study protocol requirements
• • 9. Participants with other food allergies must agree to continue avoidance of these food items from their diet to avoid confounding the safety and efficacy data of the study
• Exclusion Criteria:
• • 1. Currently in build-up phase of aeroallergen immunotherapy
• • 2. Current food allergen immunotherapy or use of any food allergen immunotherapy within the past 12 months
• • 3. Pregnant, planning a pregnancy during the study, or breast-feeding
• • 4. History of intolerance, hypersensitivity, or allergic reactions to tezepelumab, or the inactive ingredients (excipients) of tezepelumab, other IgG biologics, or rescue medications and their excipients
• • 5. Allergy to oat (participant reported)
• • 6. History of severe systemic allergic reaction to peanut with symptoms including the need for mechanical ventilation and/or severe hypotension requiring intensive care unit admission
• • 7. Asthma requiring high dose inhaled corticosteroid therapy for control (2007 NHLBI Criteria Steps 5 or 6 in adults and adolescents)
• • 8. History of a life-threatening asthma attack within 1 year before screening (e.g., requiring an ICU admission or intubation with mechanical ventilation), need for oral corticosteroids for asthma management within the last 6 months, or current Asthma Control Test score less than 19 at screening
• • 9. History of ischemic cardiovascular disease or other cardiac disease, where, in the opinion of the site investigator, participation in the trial would pose a risk from participation in the study
• • 10. History of eosinophilic gastrointestinal disease at screening
• • 11. History of disease affecting the immune system such as autoimmune disease (e.g., systemic lupus erythematosus), immune complex disease (e.g., serum sickness), or immunodeficiency, where, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
• • 12. History of malignancy of any type, excluding basal cell and squamous cell cancers of the skin that only required surgical excision or in situ carcinoma of the cervix study provided that curative therapy was completed at least 12 months prior to informed consent
• • 13. Current known helminth infection
• • 14. Positive QuantiFERON - TB Gold test or TB Gold Plus, or T-SPOT(R) TB test unless the potential participant has been treated with appropriate chemoprophylaxis. In the case of an indeterminate or borderline Interferon Gamma Release Assay (IGRA), an IGRA may be repeated
• 15. Any of the following:
• • 1. HIV
• • 2. current or prior infection with hepatitis B virus (HBV)
• • 3. current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response \>= 12 weeks
• 16. Active liver disease, defined as either:
• • 1. AST, ALT, and/or Alk phos \>2x ULN, or
• • 2. other active liver disease which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
• 17. Any of the following:
• • 1. Current use of beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers
• • 2. Received any investigational product within the past 4 months or 5 half-lives (whichever is longer) prior to screening
• • 3. Received systemic corticosteroids within 14 days prior to screening
• • 4. Receipt of immunoglobulin or other blood product within 30 days of screening
• • 5. Receipt of live attenuated vaccine within 30 days of informed consent
• • 6. Use of an immunosuppressant or immunomodulating drug within 30 days prior to screening
• • 7. Use of biologics targeting the human immune system within the past 12 months prior to screening
• • 8. Use of any herbal medications, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
• • 18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the site investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study